FDA Reconsiders Rejected Rare-Cancer Drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA will reopen its review of the rare‑cancer drug it rejected a few months ago, citing new data and internal reassessment.
- Sanofi is the maker of the drug under reconsideration, hoping the FDA’s reversal will restore its market entry and recoup development costs.
- Trump administration touts secret drug‑pricing deals that claim massive projected savings, yet outside experts say the math can’t be independently verified.
- White House pressure on the FDA is alleged by former officials, intensifying claims of political interference in the agency’s review process.
Why it matters: Sanofi's one rare‑cancer drug gets a second look, giving patients a potential therapy while forcing the FDA to defend its review integrity, slowing future approvals.
